Dyne Therapeutics Management

Management criteria checks 2/4

Dyne Therapeutics' CEO is John Cox, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.011% of the company’s shares, worth $260.71K. The average tenure of the management team and the board of directors is 3.3 years and 4.5 years respectively.

Key information

John Cox

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.01%
Management average tenure	3.3yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

Jan 11

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Jan 08

CEO

John Cox (60 yo)

less than a year

Tenure

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He serves as Chairman of the Board at Minovia Therapeutics LTD. He joined Minov...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Susanna High	Chief Operating Officer	3.8yrs	US$2.04m	0.013% $ 286.2k
Jonathan McNeill	Chief Business Officer	2.8yrs	US$2.23m	0.0074% $ 167.7k
John Cox	CEO, President & Director	less than a year	no data	0.011% $ 260.7k
Romesh Subramanian	Co-Founder & Advisor	no data	US$4.37m	no data
Richard Scalzo	Senior VP and Head of Finance & Administration	3.8yrs	no data	0.0042% $ 95.5k
John Najim	Chief Technical Officer	1.1yrs	no data	no data
Oxana Beskrovnaya	Chief Scientific Officer	2.9yrs	US$1.49m	0.019% $ 422.1k
Amy Reilly	Senior VP and Head of Corporate Communications & Investor Relations	3.8yrs	no data	no data
Daniel Wilson	Senior VP & Head of Legal	3.9yrs	no data	no data
Kate Mitchell	VP & Head of Human Resources	1.8yrs	no data	no data
Debra Feldman	Chief Regulatory Affairs Officer	4yrs	no data	no data
Ashish Dugar	Chief Medical Affairs Officer	3.3yrs	no data	no data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: DYN's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Cox	CEO, President & Director	less than a year	no data	0.011% $ 260.7k
Sudhir Agrawal	Member of Scientific Advisory Board	no data	no data	no data
Edward Hurwitz	Independent Director	5.5yrs	US$93.82k	0% $ 0
David Lubner	Independent Director	4.2yrs	US$264.17k	0.061% $ 1.4m
Jason Rhodes	Independent Chairman	6.4yrs	US$283.17k	0% $ 0
Dirk Kersten	Independent Director	5.5yrs	US$262.67k	0% $ 0
Francesco Muntoni	Member of Scientific Advisory Board	3.8yrs	no data	no data
Louis Kunkel	Member of Scientific Advisory Board	no data	no data	no data
Nancy Andrews	Member of Scientific Advisory Board	no data	no data	no data
Catherine Stehman-Breen	Independent Director	4.9yrs	US$253.92k	0.10% $ 2.3m
Charles Thornton	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Statland	Member of Scientific Advisory Board	4yrs	no data	no data

4.5yrs

Average Tenure

60yo

Average Age

Experienced Board: DYN's board of directors are considered experienced (4.5 years average tenure).

Dyne Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

Recent updates

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics, Inc. Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Dyne Therapeutics Presents New Preclinical Data from Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

Dyne Therapeutics, Inc. Announces New Preclinical Data from Its Myotonic Dystrophy Type 1 Program Will Be Featured in Presentations During the American Society of Gene & Cell Therapy

Dyne Therapeutics, Inc. Appoints Wildon Farwell as Chief Medical Officer

New 90-day low: US$17.71

Dyne Therapeutics Appoints Ashish Dugar as Senior Vice President, Global Head of Medical Affairs

New 90-day low: US$18.40

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $168 million.

Dyne Therapeutics, Inc. Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study